Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor

Cancer Biology and Therapy

Volumn 17, Issue 2, 2016, Pages 129-138

  Kivlin, Christine M ^a,b   Watson, Kelsey L ^a   Al Sannaa, Ghadah A ^c   Belousov, Roman ^a   Ingram, Davis R ^a   Huang, Kai Lieh ^b,d   May, Caitlin D ^a,b   Bolshakov, Svetlana ^a   Landers, Sharon M ^a   Kalam, Azad Abul ^a   Slopis, John M ^a   McCutcheon, Ian E ^a   Pollock, Raphael E ^e   Lev, Dina ^f   Lazar, Alexander J ^a,b   Torres, Keila E ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

AZD2281 (Olaparib); malignant peripheral nerve sheath tumor (MPNST); PARP inhibitor; poly (ADP) ribose polymerase (PARP); soft tissue sarcoma

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; OLAPARIB; VELIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PARP1 PROTEIN, HUMAN; PARP2 PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DNA REPAIR; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; EXPERIMENTAL LUNG METASTASIS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; NEURILEMMOMA; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA REPAIR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEURILEMMOMA; PHTHALAZINES; PIPERAZINES; POLY (ADP-RIBOSE) POLYMERASE-1; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961218145     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2015.1108486     Document Type: Article

References (44)

1. M.Farid, E.G.Demicco, R.Garcia, L.Ahn, P.R.Merola, A.Cioffi, R.G.Maki. Malignant peripheral nerve sheath tumors. Oncologist 2014; 19:193-201; PMID:24470531; http://dx.doi.org/10.1634/theoncologist.2013-0328
2. G.Gupta, A.Maniker. Malignant peripheral nerve sheath tumors. Neurosurg Focus 2007; 22:E12; PMID:17613203; http://dx.doi.org/10.3171/foc.2007.22.6.13
3. J.M.Friedman. Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999; 89:1-6; PMID:10469430; http://dx.doi.org/10.1002/(SICI)1096-8628(19990326)89:1%3c1::AID-AJMG3%3e3.0.CO;2-8
4. B.S.Ducatman, B.W.Scheithauer, D.G.Piepgras, H.M.Reiman, D.M.Ilstrup. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57:2006-21; PMID:3082508; http://dx.doi.org/10.1002/1097-0142(19860515)57:10%3c2006::AID-CNCR2820571022%3e3.0.CO;2-6
5. M.L.Blakely, W.W.Spurbeck, A.S.Pappo, C.B.Pratt, C.Rodriguez-Galindo, V.M.Santana, T.E.Merchant, M.Prichard, B.N.Rao. The impact of margin of resection on outcome in pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Pediatr Surg 1999; 34:672-5; PMID:10359161; http://dx.doi.org/10.1016/S0022-3468(99)90353-6
6. M.Carli, A.Ferrari, A.Mattke, I.Zanetti, M.Casanova, G.Bisogno, G.Cecchetto, R.Alaggio, L.De Sio, E.Koscielniak, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol 2005; 23:8422-30; PMID:16293873; http://dx.doi.org/10.1200/JCO.2005.01.4886
7. C.Zou, K.D.Smith, J.Liu, G.Lahat, S.Myers, W.L.Wang, W.Zhang, I.E.McCutcheon, J.M.Slopis, A.J.Lazar, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009; 249:1014-22; PMID:19474676; http://dx.doi.org/10.1097/SLA.0b013e3181a77e9a
8. W.W.Wong, T.Hirose, B.W.Scheithauer, S.E.Schild, L.L.Gunderson. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998; 42:351-60; PMID:9788415; http://dx.doi.org/10.1016/S0360-3016(98)00223-5
9. M.Anghileri, R.Miceli, M.Fiore, L.Mariani, A.Ferrari, C.Mussi, L.Lozza, P.Collini, P.Olmi, P.G.Casali, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006; 107:1065-74; PMID:16881077; http://dx.doi.org/10.1002/cncr.22098
10. N.McCabe, C.J.Lord, A.N.Tutt, N.M.Martin, G.C.Smith, A.Ashworth. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005; 4:934-6; PMID:16251802; http://dx.doi.org/10.4161/cbt.4.9.2141
11. N.McCabe, N.C.Turner, C.J.Lord, K.Kluzek, A.Bialkowska, S.Swift, S.Giavara, M.J.O'Connor, A.N.Tutt, M.Z.Zdzienicka, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66:8109-15; PMID:16912188; http://dx.doi.org/10.1158/0008-5472.CAN-06-0140
12. J.C.Ame, C.Spenlehauer, G.de Murcia. The PARP superfamily. Bioessays 2004; 26:882-93; PMID:15273990; http://dx.doi.org/10.1002/bies.20085
13. H.Farmer, N.McCabe, C.J.Lord, A.N.Tutt, D.A.Johnson, T.B.Richardson, M.Santarosa, K.J.Dillon, I.Hickson, C.Knights, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21; PMID:15829967; http://dx.doi.org/10.1038/nature03445
14. H.E.Bryant, N.Schultz, H.D.Thomas, K.M.Parker, D.Flower, E.Lopez, S.Kyle, M.Meuth, N.J.Curtin, T.Helleday. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7; PMID:15829966; http://dx.doi.org/10.1038/nature03443
15. E.R.Plummer. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 2006; 6:364-8; PMID:16753340; http://dx.doi.org/10.1016/j.coph.2006.02.004
16. A.Meindl, N.Ditsch, K.Kast, K.Rhiem, R.K.Schmutzler. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int 2011; 108:323-30; PMID:21637635; http://dx.doi.org/10.3238/arztebl.2011.0323
17. T.Nasuno, S.Mimaki, M.Okamoto, H.Esumi, K.Tsuchihara. Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines. Cancer Sci 2014; 105:202-10; PMID:24219164; http://dx.doi.org/10.1111/cas.12322
18. I.Faraonia, M.Compagnone, S.Lavorgna, D.F.Angelini, M.T.Cencioni, E.Piras, P.Panetta, T.Ottone, S.Dolci, A.Venditti, et al. BRCA1, PARP1 and γH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib. Biochimica et Biophysica Acta (BBA) - Mol Basis Dis 2015; 1852:462-72; PMID:25483710; http://dx.doi.org/10.1016/j.bbadis.2014.12.001
19. D.G.van Vuurden, E.Hulleman, O.L.Meijer, L.E.Wedekind, M.Kool, H.Witt, P.W.Vandertop, T.Wurdinger, D.P.Noske, G.J.Kaspers, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011; 2:984-96; PMID:22184287; http://dx.doi.org/10.18632/oncotarget.362
20. L.A.Byers, J.Wang, M.B.Nilsson, J.Fujimoto, P.Saintigny, J.Yordy, U.Giri, M.Peyton, Y.H.Fan, L.Diao, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2012; 2:798-811; PMID:22961666; http://dx.doi.org/10.1158/2159-8290.CD-12-0112
21. Y.Fang, A.Elahi, R.C.Denley, P.H.Rao, M.F.Brennan, S.C.Jhanwar. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. Anticancer Res 2009; 29:1255-62; PMID:19414372
22. M.Upadhyaya. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci (Landmark Ed) 2011; 16:937-51; PMID:21196210; http://dx.doi.org/10.2741/3727
23. J.D.Peacock, D.Cherba, K.Kampfschulte, M.K.Smith, N.R.Monks, C.P.Webb, M.Steensma. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J Transl Med 2013; 11:213; PMID:24040940; http://dx.doi.org/10.1186/1479-5876-11-213
24. A.J.Lazar, P.Das, D.Tuvin, B.Korchin, Q.Zhu, Z.Jin, C.L.Warneke, P.S.Zhang, V.Hernandez, D.Lopez-Terrada, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 2007; 13:7314-21; PMID:18094412; http://dx.doi.org/10.1158/1078-0432.CCR-07-0174
25. K.E.Torres, Q.S.Zhu, K.Bill, G.Lopez, M.P.Ghadimi, X.Xie, E.D.Young, J.Liu, T.Nguyen, S.Bolshakov, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res 2011; 17:3943-55; PMID:21540237; http://dx.doi.org/10.1158/1078-0432.CCR-11-0193
26. Z.Jin, G.Lahat, B.Korchin, T.Nguyen, Q.S.Zhu, X.Wang, A.J.Lazar, J.Trent, R.E.Pollock, D.Lev. Midkine enhances soft-tissue sarcoma growth: a possible novel therapeutic target. Clin Cancer Res 2008; 14:5033-42; PMID:18698021; http://dx.doi.org/10.1158/1078-0432.CCR-08-0092
27. G.Lopez, J.Liu, W.Ren, W.Wei, S.Wang, G.Lahat, Q.S.Zhu, W.G.Bornmann, D.J.McConkey, R.E.Pollock, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009; 15:3472-83; PMID:19417021; http://dx.doi.org/10.1158/1078-0432.CCR-08-2714
28. G.Lopez, K.Torres, J.Liu, B.Hernandez, E.Young, R.Belousov, S.Bolshakov, A.J.Lazar, J.M.Slopis, I.E.McCutcheon, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res 2011; 71:185-96; PMID:21084276; http://dx.doi.org/10.1158/0008-5472.CAN-10-2799
29. W.Ren, B.Korchin, G.Lahat, C.Wei, S.Bolshakov, T.Nguyen, W.Merritt, A.Dicker, A.Lazar, A.Sood, et al. Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res 2008; 14:5466-75; PMID:18765538; http://dx.doi.org/10.1158/1078-0432.CCR-08-0562
30. O.Goertz, S.Langer, D.Uthoff, A.Ring, I.Stricker, A.Tannapfel, H.U.Steinau. Diagnosis, treatment and survival of 65 patients with malignant peripheral nerve sheath tumors. Anticancer Res 2014; 34:777-83; PMID:24511012
31. S.C.Jhanwar, Q.Chen, F.P.Li, M.F.Brennan, J.M.Woodruff. Cytogenetic analysis of soft tissue sarcomas. Recurrent chromosome abnormalities in malignant peripheral nerve sheath tumors (MPNST). Cancer Genet Cytogenet 1994; 78:138-44; PMID:7828144; http://dx.doi.org/10.1016/0165-4608(94)90081-7
32. F.Mertens, P.Dal Cin, I.De Wever, C.D.Fletcher, N.Mandahl, F.Mitelman, J.Rosai, A.Rydholm, R.Sciot, G.Tallini, et al. Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol 2000; 190:31-8; PMID:10640989; http://dx.doi.org/10.1002/(SICI)1096-9896(200001)190:1%3c31::AID-PATH505%3e3.0.CO;2-
33. E.P.Rahrmann, A.L.Watson, V.W.Keng, K.Choi, B.S.Moriarity, D.A.Beckmann, N.K.Wolf, A.Sarver, M.H.Collins, C.L.Moertel, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet 2013; 45:756-66; PMID:23685747; http://dx.doi.org/10.1038/ng.2641
34. D.Bradford, A.Kim. Current treatment options for malignant peripheral nerve sheath tumors. Curr Treat Options Oncol 2015; 16:328; PMID:25777573; http://dx.doi.org/10.1007/s11864-015-0328-6
35. R.G.Maki, D.R.D'Adamo, M.L.Keohan, M.Saulle, S.M.Schuetze, S.D.Undevia, M.B.Livingston, M.M.Cooney, M.L.Hensley, M.M.Mita, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009; 27:3133-40; PMID:19451436; http://dx.doi.org/10.1200/JCO.2008.20.4495
36. A.Kim, E.Dombi, K.Tepas, E.Fox, S.Martin, P.Wolters, F.M.Balis, N.Jayaprakash, B.Turkbey, N.Muradyan, et al. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas. Pediatr Blood Cancer 2013; 60:396-401; PMID:22961690; http://dx.doi.org/10.1002/pbc.24281
37. K.A.Robertson, G.Nalepa, F.C.Yang, D.C.Bowers, C.Y.Ho, G.D.Hutchins, J.M.Croop, T.A.Vik, S.C.Denne, L.F.Parada, et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13:1218-24; PMID:23099009; http://dx.doi.org/10.1016/S1470-2045(12)70414-X
38. S.Rottenberg, J.E.Jaspers, A.Kersbergen, E.van der Burg, A.O.Nygren, S.A.Zander, P.W.Derksen, M.de Bruin, J.Zevenhoven, A.Lau, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105:17079-84; PMID:18971340; http://dx.doi.org/10.1073/pnas.0806092105
39. F.A.Dungey, D.A.Loser, A.J.Chalmers. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008; 72:1188-97; PMID:18954712; http://dx.doi.org/10.1016/j.ijrobp.2008.07.031
40. V.J.Weston, C.E.Oldreive, A.Skowronska, D.G.Oscier, G.Pratt, M.J.Dyer, G.Smith, J.E.Powell, Z.Rudzki, P.Kearns, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 2010; 116:4578-87; PMID:20739657; http://dx.doi.org/10.1182/blood-2010-01-265769
41. K.A.Menear, C.Adcock, R.Boulter, X.L.Cockcroft, L.Copsey, A.Cranston, K.J.Dillon, J.Drzewiecki, S.Garman, S.Gomez, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008; 51:6581-91; PMID:18800822; http://dx.doi.org/10.1021/jm8001263
42. C.T.Williamson, H.Muzik, A.G.Turhan, A.Zamo, M.J.O'Connor, D.G.Bebb, S.P.Lees-Miller. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010; 9:347-57; PMID:20124459; http://dx.doi.org/10.1158/1535-7163.MCT-09-0872
43. J.Goswami, S.Goyal, H.Wu, M.S.Moran, B.G.Haffty. Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS plus RT). J Clin Oncol 2010; 28: 15s: 582
44. A.S.M.Gennari, L.Varesco, et al. Prognostic significance of BRCA1, PARP1 and PARP2 in sporadic breast cancer. J Clin Oncol 2009; 27s:e22114